Lundbeck to present new Vyepti and bocunebart data at EAN 2026

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in Geneva. The company said five presentations will showcase its current and future approaches to migraine prevention, including new analyses for eptinezumab and primary phase 2b PROCEED data for the investigational treatment bocunebart. Lundbeck said the […]